Roche
2023
The pharmaceutical industry is one of Germany’s most important export industries. In recent years, the export of pharmaceutical products has seen above-average growth compared to the other export sectors. In addition, research and development play a prominent role for pharmaceutical companies.
Our new study for Roche focuses on these two aspects. It examines the extent to which the German pharmaceutical industry is particularly value-added intensive and innovative in its exports.
Compared to those in the other industries, German pharmaceutical exports are characterised by above-average value-added intensity and growth dynamics. This means that the export of pharmaceutical products (for example, worth one million euros) is linked to more domestic value added and jobs than the average German export of one million euros.
In an international comparison, the German pharmaceutical industry is shown to be one of the most important players on the world market and has been able to maintain its share of world exports in recent years.
In terms of research, the German pharmaceutical industry is losing ground on its international competitors:
For this detailed investigation of the German pharmaceutical industry in a national and international comparison, we relied on the available statistical data. This was then analysed with the help of the Prognos model landscape.
To the study (PDF in German)
Further information, in German (Roche website)
Project team: Dr Georg Klose, Dr Andreas Sachs, Johann Weiss
Latest update: 07.12.2023
Senior Project Manager
The current global economic order is faltering. What does this mean for Germany and the EU? We have developed various scenarios for the future global economy for the vbw.
The EU Commission commissioned Prognos, Idea Consult and the nova-Institute to research and promote the transition to a bioeconomy in the European Union.
What impact do global crises have on regional labour markets? The 15th issue of TerritoriALL magazine reports on the OVERLAP project carried out by Prognos.
The Single Market Programme promotes the EU internal market in order to strengthen it, standardise it and make it more competitive. Prognos was involved in the mid-term evaluation of the programme.
Prognos is supporting the North Rhine-Westphalian Ministry of the Environment in organising, implementing and establishing the world's first trade exhibition for the climate adaptation industry.
The Public Sector Loan Facility is an EU financial instrument to ensure a socially just transition to climate neutrality in the regions. Prognos and t33 srl evaluated the instrument.
German industry is heavily dependent on raw materials and intermediate products from abroad, especially from China. Prognos analysed supply chains and developed recommendations for action.
How can innovations be implemented in practice? This is where the BMBF's ‘Innovative University’ funding initiative comes in. Prognos and Fraunhofer ISI are evaluating the programme.
On behalf of the BMWK, we evaluate the impact of the BEG in the funding period 2021 – 2025 together with ifeu, ITG, and FIW.
Specialists waste a lot of time on tiresome routine tasks. 3D planning tools or digital twins can help. Our analysis for the Fraunhofer IGD shows which professional groups benefit directly from their digital technologies.
Prognos is one of the oldest economic research centres in Europe. Founded at the University of Basel, Prognos experts have been conducting research for a wide range of clients from the public and private sectors since 1959 – politically independent, scientifically sound.